Detalhe da pesquisa
1.
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors.
Eur Respir J
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697649
2.
Pulmonary vascular phenotype identified in patients with GDF2 (BMP9) or BMP10 variants: an international multicentre study.
Eur Respir J
; 63(4)2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38514094
3.
Differential responses of pulmonary vascular cells from PAH patients and controls to TNFα and the effect of the BET inhibitor JQ1.
Respir Res
; 24(1): 193, 2023 Jul 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516840
4.
Dietary intake and glutamine-serine metabolism control pathologic vascular stiffness.
Cell Metab
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38701775
5.
Diagnosis and management of pulmonary veno-occlusive disease.
Expert Rev Respir Med
; 17(8): 635-649, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37578057
6.
Pulmonary hypertension associated with diazoxide: the SUR1 paradox.
ERJ Open Res
; 9(6)2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37965230
7.
Monitoring of Hemodynamics With Right Heart Catheterization in Children With Pulmonary Arterial Hypertension.
J Am Heart Assoc
; 12(7): e029085, 2023 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36974756
8.
The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload.
Front Cardiovasc Med
; 9: 1063967, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588576